Search

Your search keyword '"Prévost, G"' showing total 564 results
Start Over Author "Prévost, G"
564 results on '"Prévost, G"'

3. Treating diabetes with islet transplantation: Lessons from the past decade in Lille

Author

Balavoine, A.S., Bresson, R., Bourdelle-Hego, M.F., Cazaubiel, M., Cordonnier, M., Delefosse, D., Dorey, F., Fayard, A., Fermon, C., Fontaine, P., Gillot, C., Haye, S., Le Guillou, A.C., Karrouz, W., Lemaire, C., Lepeut, M., Leroy, R., Mycinski, B., Parent, E., Siame, C., Sterkers, A., Torres, F., Verier-Mine, O., Verlet, E., Desailloud, R., Dürrbach, A., Godin, M., Lalau, J.D., Lukas-Croisier, C., Thervet, E., Toupance, O., Reznik, Y., Westeel, P.F., Vantyghem, M.-C., Defrance, F., Quintin, D., Leroy, C., Raverdi, V., Prévost, G., Caiazzo, R., Kerr-Conte, J., Glowacki, F., Hazzan, M., Noel, C., and Pattou, F.

Published
2014
Full Text
View/download PDF

5. Staphylococcal Pore-Forming Toxins

Author

Prévost, G., Mourey, L., Colin, D. A., Menestrina, G., Compans, R. W., editor, Cooper, M., editor, Ito, Y., editor, Koprowski, H., editor, Melchers, F., editor, Oldstone, M., editor, Olsnes, S., editor, Potter, M., editor, Vogt, P. K., editor, Wagner, H., editor, and van der Goot, F. Gisou, editor

Published
2001
Full Text
View/download PDF

17. Évaluation des effets centraux du neuropeptide 26RFa sur la régulation de la glycémie chez la souris high fat diet

Author

Le Solliec, M.A., primary, Maucotel, J., additional, Arabo, A., additional, Takhlidjt, S., additional, Picot, M., additional, Riancho, J., additional, Lefranc, B., additional, Leprince, J., additional, Do Rego, J.L., additional, Do Rego, J.C., additional, Nedelec, E., additional, Benani, A., additional, Youssef, A., additional, Chartrel, N., additional, and Prévost, G., additional

Published
2021
Full Text
View/download PDF

39. Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer

Author

Namer, M, Soler-Michel, P, Turpin, F, Chinet-Charrot, P, de Gislain, C, Pouillart, P, Delozier, T, Luporsi, E, Etienne, P.L, Schraub, S, Eymard, J.C, Serin, D, Ganem, G, Calais, G, Maillart, P, Colin, P, Trillet-Lenoir, V, Prevost, G, Tigaud, D, Clavère, P, Marti, P, Romieu, G, and Wendling, J.L

Published
2001
Full Text
View/download PDF

45. Efficacité et tolérance des traitements anti-fibrosants chez les patients porteurs d’une mutation du complexe telomèrase

Author

Justet, A., Klay, D., Cottin, V., Nunes, H., Molina Molina, M., Reynaud-Gaubert, M., Naccache, J.M., Manali, E., Froidure, A., Wemeau, L., Gondouin, A., Bonniaud, P., Andrejak, C., Hirschi, S., Stéphane, J., Tromeur, C., Prevost, G., Marchand-Adam, S., Gamez, A.S., Kannengiesser, C., Van Moorsel, C., Crestani, B., and Borie, R.

Published
2019
Full Text
View/download PDF

46. Dumping syndrome et agonistes du GLP-1

Author

Pautasso, V., primary, Bons, J., additional, Menon, S., additional, Cailleux, A.F., additional, Savouré, A., additional, Durand, K., additional, Lefebvre, H., additional, and Prévost, G., additional

Published
2016
Full Text
View/download PDF

49. Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly : results of a prospective multicenter clinical trial

Author

Caron, Pj, Bevan, Js, Petersenn, S, Flanagan, D, Tabarin, A, Prévost, G, Maisonobe, P, Clermont, A, Van Gaal Luc, L, Marek, J, Nuutila, P, Välimäki, M, Ajzenberg, C, Borson Chazot, F, Brue, T, Caron, P, Chabre, O, Chanson, P, Rudelli, C, Delemer, B, Kuhn, Jm, Badenhoop, K, Berg, C, Schöfl, C, Schopohl, J, Cannavo', Salvatore, Colao, A, De Marinis, L, Stades, A, Van der Lely, A, Kadioğlu, P, Bevan, J, Trainer, P., and Berg, Christian (Beitragende*r)

Subjects
Adenoma, Adult, Male, medicine.medical_specialty, Adolescent, acromegaly, somatostatin analogs, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Clinical Biochemistry, Medizin, Context (language use), Lanreotide, Biochemistry, Peptides, Cyclic, chemistry.chemical_compound, Young Adult, Endocrinology, Internal medicine, Acromegaly, medicine, Clinical endpoint, Humans, Neoadjuvant therapy, Aged, Intention-to-treat analysis, business.industry, Surrogate endpoint, Endocrine Care, Biochemistry (medical), Middle Aged, medicine.disease, Neoadjuvant Therapy, Tumor Burden, Clinical trial, Treatment Outcome, chemistry, Female, Growth Hormone-Secreting Pituitary Adenoma, business, Somatostatin, Gels
Abstract

Context: Methodological shortcomings often compromise investigations into the effects of primary somatostatin-analog treatment on tumor size in acromegaly. There are also limited data for the long-acting lanreotide formulation. Objective: The aim of the study was to better characterize the effects of primary lanreotide Autogel treatment on tumor size in patients with GH-secreting macroadenomas. Design: PRIMARYS was a 48-week, multicenter, open-label, single-arm study. Setting: The study was conducted at specialist endocrine centers. Patients: Treatment-naïve acromegalic patients with GH-secreting macroadenomas participated in the study. Intervention: Lanreotide Autogel 120 mg was administered sc every 28 days (without dose titration). Outcome Measures: The primary endpoint was the proportion of patients with clinically significant (≥20%) tumor volume reduction (TVR) at week 48/last post-baseline value available using central assessments from three readers. The null hypothesis (H0) for the primary endpoint was that the proportion with TVR was ≤55%. Secondary endpoints included: TVR at other time points, GH and IGF-1, acromegalic symptoms, quality of life (QoL), and safety. Results: Sixty-four of 90 (71.1%) patients completed the study. Clinically significant TVR at 48 weeks/last post-baseline value available was achieved by 62.9% (95% confidence interval, 52.0, 72.9) of 89 patients in the primary analysis (intention-to-treat population; H0 not rejected) and 71.9–75.3% in sensitivity (n = 89) and secondary analyses (n = 63) (H0 rejected). At 12 weeks, 54.1% had clinically significant TVR. Early and sustained improvements also occurred in GH and IGF-1, acromegalic symptoms, and QoL. No patients withdrew due to gastrointestinal intolerance. Conclusions: Primary treatment with lanreotide Autogel, administered at 120 mg (highest available dose) without dose titration, in patients with GH-secreting macroadenomas provides early and sustained reductions in tumor volume, GH and IGF-1, and acromegalic symptoms, and improves QoL.

Published
2014

50. Composition of Staphylococcal Bi-Component Toxins Determines Pathophysiological Reactions

Author

B König, Wolfgang König, and Prévost G

Subjects
Microbiology (medical), Staphylococcus aureus, Cell Survival, Bacterial Toxins, Leukocidin, medicine.disease_cause, Histamine Release, Microbiology, Hemolysin Proteins, chemistry.chemical_compound, Bacterial Proteins, Leukocidins, medicine, Humans, Coloring Agents, skin and connective tissue diseases, Gene, Glucuronidase, Dose-Response Relationship, Drug, biology, Toxin, Interleukin-8, Interleukin, Biological activity, Trypan Blue, General Medicine, respiratory system, biochemical phenomena, metabolism, and nutrition, bacterial infections and mycoses, Enzyme assay, chemistry, Enzyme Induction, Luminescent Measurements, biology.protein, bacteria, Histamine, Granulocytes
Abstract

Summary Staphylococcus aureus produces numerous bi-component toxins, e.g., Panton-Valentine leukocidin (Luk-PVL) and γ-haemolysin, which consist of type S and F proteins. Previous studies showed that Luk-PVL induces inflammatory mediator release from human granulocytes that might reflect the in-vivo effects, e.g., dermonecrosis by Luk-PVL. Clinical isolates not only harbour the two genes coding for Luk-PVL (S-protein: LukS-PVL, F-protein: LukF-PVL) but also the three genes encoding γ-haemolysin (S-protein: HlgA, HlgB; F-protein: HlgC). The interaction of all the possible potential toxins with human granulocytes was studied with regard to the generation of oxygen metabolites (chemiluminescence response), enzyme activity (β-glucuronidase) and histamine release as well as interleukin (IL)-8 generation. The data clearly show that the individual subunits (S, F) differ in their activities. The following activities were obtained for the S components: LukS-PVL > HlgC > HlgA: the F components LukF-PVL and HlgB were similarly active. Thus, the toxins LukS-PVL/LukF-PVL and LukS-PVL/HlgB were the most potent inducers of inflammatory mediator release from human granulocytes, followed by HlgC/LukF-PVL and HlgC/HlgB and to a lesser degree by the toxins HlgA/LukF-PVL and HlgA/HlgB. The data indicate that class S components and class F components are interchangeable and give toxins with genuine biological activities.

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results